{"filing":{"accession_number":"0001628280-26-043170","cik":"0001649904","ticker":"RYTM","company_name":"RHYTHM PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"rytm-20260613.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026043170/rytm-20260613.htm"},"events":[{"id":11026,"run_id":9664,"accession_number":"0001628280-26-043170","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Rhythm Pharmaceuticals disclosed interim Phase 2 trial data for setmelanotide in Prader-Willi syndrome and other obesity-related indications, along with multiple clinical data presentations at the Endocrine Society's Annual Meeting (ENDO 2026), including efficacy and safety results showing BMI reductions and improvements in hyperphagia. This material clinical development milestone affects investor assessment of the company's pipeline and commercial prospects but does not fit the standard 8-K event taxonomy.","company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7506,"accession_number":"0001628280-26-043170","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Rhythm Pharmaceuticals disclosed interim Phase 2 trial data for setmelanotide in Prader-Willi syndrome patients and multiple data presentations at the Endocrine Society's Annual Meeting. While this is clinical trial data disclosure rather than a traditional earnings release, the announcement of interim efficacy/safety data from an exploratory Phase 2 trial is material to investors evaluating the company's pipeline and clinical progress. The disclosure does not fit neatly into the standard taxonomy categories (not earnings, not M\u0026A, not an executive event), making \"other_material\" the most appropriate classification for this clinical development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:09:59.537896+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7507,"accession_number":"0001628280-26-043170","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This Item 8.01 disclosure announces interim Phase 2 trial data for setmelanotide in PWS patients and multiple clinical data presentations at ENDO 2026, including efficacy and safety results across several indications (PWS, acquired hypothalamic obesity, Bardet-Biedl syndrome). While the disclosure centers on clinical trial results and real-world evidence rather than a discrete event like M\u0026A, restatement, or executive change, the breadth and materiality of positive clinical data—including BMI reductions, improvements in hyperphagia, and real-world weight loss outcomes—would affect a reasonable investor's assessment of the company's pipeline and commercial prospects. This is material clinical progress disclosure that does not fit neatly into the more specific event categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:09:59.537896+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7506,"accession_number":"0001628280-26-043170","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Rhythm Pharmaceuticals disclosed interim Phase 2 trial data for setmelanotide in Prader-Willi syndrome patients and multiple data presentations at the Endocrine Society's Annual Meeting. While this is clinical trial data disclosure rather than a traditional earnings release, the announcement of interim efficacy/safety data from an exploratory Phase 2 trial is material to investors evaluating the company's pipeline and clinical progress. The disclosure does not fit neatly into the standard taxonomy categories (not earnings, not M\u0026A, not an executive event), making \"other_material\" the most appropriate classification for this clinical development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:09:59.537896+00:00","company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","filing_date":"2026-06-15"},{"id":7507,"accession_number":"0001628280-26-043170","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This Item 8.01 disclosure announces interim Phase 2 trial data for setmelanotide in PWS patients and multiple clinical data presentations at ENDO 2026, including efficacy and safety results across several indications (PWS, acquired hypothalamic obesity, Bardet-Biedl syndrome). While the disclosure centers on clinical trial results and real-world evidence rather than a discrete event like M\u0026A, restatement, or executive change, the breadth and materiality of positive clinical data—including BMI reductions, improvements in hyperphagia, and real-world weight loss outcomes—would affect a reasonable investor's assessment of the company's pipeline and commercial prospects. This is material clinical progress disclosure that does not fit neatly into the more specific event categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:09:59.537896+00:00","company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","filing_date":"2026-06-15"}]}